检索结果-南通市图书馆

World Journal of Pediatrics 2024年第3期20卷 287-293页

作者： Dinesh Babu Somasundaram Andrew Maher Sheeja Aravindan Zhongxin Yu Brian MBesch Natarajan Aravindan department of radiation oncology University of Oklahoma Health Sciences CenterOklahoma CityOKUSA Stephenson Cancer Center Oklahoma CityOKUSA department of Pathology University of Oklahoma Health Sciences CenterOklahoma CityOKUSA radiation Biology Laboratory University of Oklahoma Health Sciences CenterBSEB 302F941 Stanton L.Young BoulevardOklahoma CityOK 73104USA

Progressive neuroblastomas(pNBs)that defy current intensive multimodal clinical therapy(IMCT)are a significant contributor to overall childhood cancer deaths[l].Neuroblastomas(NBs)that survive first-line IMCT actively evolve to acquire genetic and molecular rearrangements and display unparalleled plasticity and evolution,which causes frequent relapses in a rapidly accelerating timeline[2-4].

关键词： neuroblastoma clinical evolve

Dual-Fields Rotational Total Skin Electron Therapy: Investigation and Implementation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Medical Physics, Clinical Engineering and radiation oncology 2024年第1期13卷 1-15页

作者： M. Ming Xu Iris Rusu Richard P. Garza Northwestern Medicine Cancer Center Warrenville and Geneva Illinois USA department of radiation oncology Loyola University Medical Center Maywood Illinois USA The Austin Center for radiation oncology Austin Texas USA

Purpose: To present a protocol of a dual-field rotational (DFR) total skin electron therapy (TSET) and to provide an assessment of clinical implementation, dosimetry properties, and skin dose evaluation. Methods and Materials: The DFR-TSET combined the Stanford 6-field and McGill rotational methods. Dual 6 MeV electron beams in high dose total skin electron mode were used for DFR-TSET on a commercial linac. Beam profiles and dosimetric properties were measured using solid phantoms. The dose rate at expanded source-to-surface distance (SSD) was a combination of static rate and rotational rate. In vivo dosimetry of patient skin was performed on patients’ skin using film, metal oxide semiconductor field-effect transistors (MOSFET), and optically stimulated luminescent dosimeters (OSLD). Results: Dual field rotational total skin electron therapy exhibited good (≤±10%) uniformity in the beam profiles in the vertical direction at an extended SSD of 332 cm with a gantry angulation of ±20˚ deviated from the horizontal direction. In-vivo measurements confirmed acceptable uniformity of the patients’ total body surfaces and revealed anatomically self-blocked or shielded areas where underdosing occurred. Conclusions: The clinical implementation of DFR-TSET effectively utilizes the special mode on a linac. This technique provides short beam-on times, uniform dose distribution, large treatment field, and reduced dose of x-ray contamination to the patients. In-vivo measurements indicate satisfactory delivery and dose uniformity of the prescribed dose. Electron boost fields are recommended at normal SSDs to address underdosed areas.

关键词： Total Skin Electron Therapy Stanford 6 Field McGill Rotation Therapy In-Vivo Dosimetry

Comprehensive genomic analysis of early and late-onset hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Genes & Diseases 2024年第4期11卷 77-81页

作者： Jialin Yang Chao Chen Song Wang Yaru Zhang Jiaohui Pang Yajun Wang Qiuxiang Ou Hao Jiang Juying Liu department of radiation oncology Sichuan Cancer Hospital&InstituteSichuan Cancer CenterSchool of MedicineUniversity of Electronic Science and Technology of ChinaChengduSichuan 610041China Jinling Hospital Department of OncologyNanjing Medical UniversityNanjingJiangsu 210002China Geneseeq Research Institute Nanjing Geneseeq Technology Inc.NanjingJiangsu 210000China department of oncology Haian Hospital of Traditional Chinese MedicineHaianJiangsu 226600China Interventional Therapy department Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjingJiangsu 210009China

Hepatocellular carcinoma(HCC)is the major histologic type of primary liver cancer,accounting for approximately 75%of liver cancer cases.'Despite many advancements in its treatment,the prognosis and drug response of HCC patients are ***,there is an unmet clinical need to explore genomic aberrations underlying early-and lateonset HcC,which might facilitate drug discovery and provide personalized biomarker-driven treatment options for these patients.

关键词： patients prognosis cancer

Targeting RAF dimers in RAS mutant tumors:From biology to clinic

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acta Pharmaceutica Sinica B 2024年第5期14卷 1895-1923页

作者： Huanhuan Yin Qiulin Tang Hongwei Xia Feng Bi Division of Abdominal Cancer Department of Medical OncologyCancer Center and Laboratory of Molecular Targeted Therapy in OncologyWest China HospitalSichuan UniversityChengdu 610041China

RAS mutations occur in approximately 30%of tumors worldwide and have a poor prognosis due to limited *** targeting of KRAS G12C has achieved significant success in recent years,but there is still a lack of efficient therapeutic approaches for tumors with non-G12C KRAS mutations.A highly promising approach is to target the MAPK pathway downstream of RAS,with a particular focus on RAF ***-generation RAF inhibitors have been authorized to treat BRAF mutant tumors for over a ***,their use in RAS-mutated tumors is not recommended due to the paradoxical ERK activation mainly caused by RAF *** address the issue of RAF dimerization,type II RAF inhibitors have emerged as leading *** clinical studies have shown the initial effectiveness of these agents against RAS mutant ***,type II RAF inhibitors in combination with MEK or ERK inhibitors have demonstrated impressive efficacy in RAS mutant *** review aims to clarify the importance of RAF dimerization in cellular signaling and resistance to treatment in tumors with RAS mutations,as well as recent progress in therapeutic approaches to address the problem of RAF dimerization in RAS mutant tumors.

关键词： RAS mutations RAF dimerization RAF inhibitors Cancer therapy Drug resistance

Accelerated partial breast irradiation:Current evidence and future developments

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Innovation 2024年第1期3卷 104-112页

作者： Dandan Song Honghong Zhang Chengbo Ren Ning Zhan Liangxi Xie Wenjia Xie department of radiation oncology Xiang'an Hospital of Xiamen UniversityCancer Research CenterSchool of MedicineXiamen UniversityXiang'anXiamenChina department of radiation oncology The First Affiliated Hospital of Hebei North UniversityZhangjiakouHebeiChina

Whole breast irradiation after breast-conserving surgery for early breast cancer has become one of the standard treatment modes for breast cancer and yields the same effect as radical *** partial breast irradiation(APBI)as a substitute for whole breast irradiation for patients with early breast cancer is a hot spot in clinical *** is characterised by simple high-dose local irradiation of the tumour bed in a short time,thus improving convenience for patients and saving *** implementation methods of APBI mainly include brachytherapy,external beam radiation therapy,and intraoperative *** review provides an overview of the clinical effects and adverse reactions of the main technologies of APBI and discusses the prospects for the future development of APBI.

关键词： accelerated partial breast irradiation brachytherapy breast cancer breast conserving surgery external beam radiation therapy intraoperative radiotherapy

Colorectal cancer and dormant metastases:Put to sleep or destroy?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal oncology 2024年第6期16卷 2304-2317页

作者： Marina A Senchukova department of oncology Orenburg State Medical UniversityOrenburg 460000Russia

After reading the review by An et al“Biological factors driving colorectal cancer metastasis”,which covers the problem of the metastasis of colorectal cancer(CRC),I had a desire to discuss with readers one of the exciting problems associated with dormant *** deaths from CRCs are caused by metastases,which can be detected both at diagnosis of the primary tumor and several years or even decades after *** is because tumor cells that enter the bloodstream can be destroyed by the immune system,cause metastatic growth,or remain dormant for a long *** tumor cells may not manifest themselves throughout a person’s life or,after some time and under appropriate conditions,may give rise to the growth of *** this editorial,we will discuss the most important features of dormant metastases and the mechanisms of premetastatic niche formation,as well as factors that contribute to the activation of dormant metastases in *** will pay special attention to the possible mechanisms involved in the formation of circulating tumor cell complexes and the choice of therapeutic strategies that promote the dormancy or destruction of tumor cells in CRCs.

关键词： Circulating tumor cells Colorectal cancer Disseminated tumor cells Dormant metastases Metastases Premetastatic niche

Artificial intelligence-driven radiomics study in cancer:the role of feature engineering and modeling

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2024年第1期11卷 115-147页

作者： Yuan-Peng Zhang Xin-Yun Zhang Yu-Ting Cheng Bing Li Xin-Zhi Teng Jiang Zhang Saikit Lam Ta Zhou Zong-Rui Ma Jia-Bao Sheng Victor CWTam Shara WYLee Hong Ge Jing Cai department of Medical Informatics Nantong UniversityNantong 226001JiangsuChina department of Health Technology and Informatics the Hong Kong Polytechnic UniversityHong Kong 999077China The Hong Kong Polytechnic University Shenzhen Research Institute Shenzhen 518000GuangdongChina department of radiation oncology the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer HospitalZhengzhou 450008China

Modern medicine is reliant on various medical imaging technologies for non-invasively observing patients’***,the interpretation of medical images can be highly subjective and dependent on the expertise of ***,some potentially useful quantitative information in medical images,especially that which is not visible to the naked eye,is often ignored during clinical *** contrast,radiomics performs high-throughput feature extraction from medical images,which enables quantitative analysis of medical images and prediction of various clinical *** have reported that radiomics exhibits promising performance in diagnosis and predicting treatment responses and prognosis,demonstrating its potential to be a non-invasive auxiliary tool for personalized ***,radiomics remains in a developmental phase as numerous technical challenges have yet to be solved,especially in feature engineering and statistical *** this review,we introduce the current utility of radiomics by summarizing research on its application in the diagnosis,prognosis,and prediction of treatment responses in patients with *** focus on machine learning approaches,for feature extraction and selection during feature engineering and for imbalanced datasets and multi-modality fusion during statistical ***,we introduce the stability,reproducibility,and interpretability of features,and the generalizability and interpretability of ***,we offer possible solutions to current challenges in radiomics research.

关键词： Artificial intelligence Radiomics Feature extraction Feature selection Modeling Interpretability Multimodalities Head and neck cancer

Treatment patterns and survival outcomes in patients with nonmetastatic early-onset pancreatic cancer

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2024年第12期30卷 1739-1750页

作者： Le-Tian Zhang Ying Zhang Bi-Yang Cao Chen-Chen Wu Jing Wang Graduate School Chinese PLA Medical SchoolBeijing 100853China department of radiation oncology First Medical Center of Chinese PLA General HospitalBeijing 100853China department of Internal Medicine Hospital of University of Science and Technology BeijingBeijing 100083China department of Medical oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

BACKGROUND The incidence of patients with early-onset pancreatic cancer(EOPC;age≤50 years at diagnosis)is on the rise,placing a heavy burden on individuals,families,and *** role of combination therapy including surgery,radiotherapy,and chemotherapy in non-metastatic EOPC is not *** To investigate the treatment patterns and survival outcomes in patients with non-metastatic *** A total of 277 patients with non-metastatic EOPC who were treated at our institution between 2017 and 2021 were investigated *** survival(OS),disease-free survival,and progression-free survival were estimated using the Kaplan-Meier *** and multivariate analyses with the Cox proportional hazards model were used to identify prognostic *** With a median follow-up time of 34.6 months,the 1-year,2-year,and 3-year OS rates for the entire cohort were 84.3%,51.5%,and 27.6%,*** median OS of patients with localized disease who received surgery alone and adjuvant therapy(AT)were 21.2 months and 28.8 months,respectively(P=0.007).The median OS of patients with locally advanced disease who received radiotherapy-based combination therapy(RCT),surgery after neoadjuvant therapy(NAT),and chemotherapy were 28.5 months,25.6 months,and 14.0 months,respectively(P=0.002).The median OS after regional recurrence were 16.0 months,13.4 months,and 8.9 months in the RCT,chemotherapy,and supportive therapy groups,respectively(P=0.035).Multivariate analysis demonstrated that carbohydrate antigen 19-9 level,pathological grade,T-stage,N-stage,and resection were independent prognostic factors for non-metastatic *** AT improves postoperative survival in localized *** after NAT and RCT are the preferred therapeutic options for patients with locally advanced EOPC.

关键词： Pancreatic cancer Early-onset Non-metastatic Multimodal treatment Radiotherapy Overall survival

Predictive value of positive lymph node ratio in patients with locally advanced gastric remnant cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal oncology 2024年第3期16卷 833-843页

作者： Meng Zhuo Lei Tian Ting Han Teng-Fei Liu Xiao-Lin Lin Xiu-Ying Xiao department of oncology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200127China department of oncology Hebei General HospitalShijiazhuang 050051Hebei ProvinceChina

BACKGROUND Traditional lymph node stage(N stage)has limitations in advanced gastric remnant cancer(GRC)patients;therefore,establishing a new predictive stage is *** To explore the predictive value of positive lymph node ratio(LNR)according to clinicopathological characteristics and prognosis of locally advanced *** Seventy-four patients who underwent radical gastrectomy and lymphadenectomy for locally advanced GRC were retrospectively *** relationship between LNR and clinicopathological characteristics was *** survival analysis was performed using Kaplan-Meier survival curves and Cox regression *** Number of metastatic LNs,tumor diameter,depth of tumor invasion,Borrmann type,serum tumor biomarkers,and tumor-node-metastasis(TNM)stage were correlated with LNR stage and N *** analysis revealed that the factors affecting survival included tumor diameter,anemia,serum tumor biomarkers,vascular or neural invasion,combined resection,LNR stage,N stage,and TNM stage(all P<0.05).The median survival time for those with LNR0,LNR1,LNR2 and LNR3 stage were 61,31,23 and 17 mo,respectively,and the differences were significant(P=0.000).Anemia,tumor biomarkers and LNR stage were independent prognostic factors for survival in multivariable analysis(all P<0.05).CONCLUSION The new LNR stage is uniquely based on number of metastatic LNs,with significant prognostic value for locally advanced GRC,and could better differentiate overall survival,compared with N stage.

关键词： Gastric remnant cancer Positive lymph node ratio Clinicopathological characteristics Prognosis

Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal oncology 2024年第2期16卷 557-562页

作者： Toshiaki Tsurui Yuya Hirasawa Yutaro Kubota Kiyoshi Yoshimura Takuya Tsunoda department of Medical oncology Showa UniversityTokyo 1428555Japan department of Clinical Immuno oncology Clinical Research Institute of Clinical Pharmacology and TherapeuticsShowa UniversityTokyo 1578577Japan

BACKGROUND Hyperbilirubinemia with hepatic metastases is a common complication and a poor prognostic factor for colorectal cancer(CRC).Effective drainage is often im-possible before initiating systemic chemotherapy,owing to the liver’s diffuse metastatic ***,an appropriate chemotherapeutic approach for the treatment of hyperbilirubinemia is currently *** SUMMARY The patient,a man in his 50s,presented with progressive fatigue and severe *** tomography revealed multiple hepatic masses with thick-ened walls in the sigmoid colon,which was pathologically confirmed as a well-differentiated *** RAS or BRAF mutations were *** Eastern Cooperative oncology Group(ECOG)performance status(PS)score was *** drainage was impossible due to the absence of a dilated bile duct,and panitumumab monotherapy was promptly ***,the bilirubin level decreased and then normalized,and the patient’s PS improved to zero ECOG score after four cycles of therapy without significant adverse *** Anti-EGFR antibody monotherapy is a safe and effective treatment for RAS wild-type CRC and hepatic metastases with severe hyperbilirubinemia.

关键词： Colorectal neoplasms Panitumumab Chemotherapy Hyperbilirubinemia Jaundice Case report